Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
Raffaele Nuzzi,1 Giada Geronazzo,1,2 Federico Tridico,1 Alessia Nuzzi,3 Paolo Caselgrandi,1 Antonio Giulio Piga4 1Eye Clinic Section, Department of Surgical Sciences, University of Turin, Turin, Italy; 2Regional Reference Centre for Diagnosis and Cure of Hemoglobinopathies, S. Luigi Gonzaga Universi...
Enregistré dans:
Auteurs principaux: | Nuzzi R, Geronazzo G, Tridico F, Nuzzi A, Caselgrandi P, Piga AG |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/55e38c48e15346089a76b4635cefb219 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients
par: Noppawan Phumala Morales, et autres
Publié: (2022) -
An overview of complications associated with deferoxamine therapy in thalassemia
par: Bijan Keikhaei, et autres
Publié: (2021) -
Biofortification of cowpea beans with iron: iron´s influence on mineral content and yield
par: Márquez-Quiroz,C, et autres
Publié: (2015) -
Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
par: Parisi S, et autres
Publié: (2021) -
Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers
par: Martin Hruby, et autres
Publié: (2021)